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median survival of 8 to 12 months in the 3000 new
cases reported each year in the United States.1 At least
20% of the mesotheliomas in the United States are not
associated with asbestos exposure, and less than 5% of
people exposed to a high dose of asbestos experience
the development of mesotheliomas. Thus researchers
have proposed that additional carcinogens might be
responsible for mesotheliomas in non-asbestos–
exposed individuals or might render particular individ-
uals more susceptible to the carcinogenic effects of
asbestos. 
Cicala and coworkers2 and Sweet and Hilleman3
reported that epithelial, spindle cell, and more often
mixed-type mesotheliomas, which could be character-
ized as macroscopically, microscopically, ultramicro-
scopically, and immunohistochemically identical to
H uman malignant pleural mesothelioma, an asbestos-related tumor that originates from the serosal lining
of the pleura, has no effective therapy and results in a
Background: A cohort (20%) of patients with mesothelioma will not have
an exposure to asbestos. Recently, a DNA tumor virus (simian virus 40)
has been shown to cause hamster mesotheliomas; we previously
described simian virus 40–like DNA amino terminus sequences in 29 of
48 mesotheliomas. We analyzed an additional 42 mesotheliomas to
determine (1) whether our initial observations were durable and (2) the
extent to which the simian virus 40 genome is present in mesotheliomas.
Methods: Genomic DNA was extracted from snap frozen mesothelioma
tumor samples and from the simian virus 40–induced hamster mesothe-
lioma tumor H9A. Polymerase chain reaction primers were used to
amplify various simian virus 40 large T-antigen regions including a
105–base pair amino terminus fragment, a 281–base pair carboxyl ter-
minus fragment, and a 310–base pair fragment of the enhancer promot-
er region. Endonuclease digestions and Southern blotting were used to
verify the expected product. Results: Thirty of the 42 (71%) samples
amplified T-antigen amino sequences, and specificity was verified by
Southern hybridization. Sixteen of 42 samples (38%) amplified the
appropriate size fragment for the carboxyl terminus, and digestion with
BsaB1 matched that of H9A. Twenty-two of 42 samples (52%) amplified
simian virus 40 regulatory sequences and Fok1 digestion matched that
of the hamster control tumor. Sequence analysis (4 patients) revealed
100% homology with the regulatory region of simian virus 40 strain 776.
Conclusions: These data suggest an association between the simian virus
40 virus and human mesothelioma that could be exploited for diagnos-
tic/therapeutic options including early detection and potential vaccina-
tion strategies. (J Thorac Cardiovasc Surg 1998;116:854-9)
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those seen in humans, developed within a 6-month peri-
od in 30 of the 43 hamsters injected with simian virus
40 (SV40), a DNA virus that was a known contaminant
of the polio and influenza vaccines in the late 1950s. In
collaboration with Carbone and coworkers,4 our group
previously reported that 60% (25 of 48) of human
mesotheliomas contain DNA for the amino terminus
region of T antigen (Tag), a protein associated with var-
ious DNA viruses, including SV40, which is capable of
causing malignant transformation. Neither the origin
nor the true identity of the virus responsible for the Tag
to be present in human mesotheliomas could be
answered with these preliminary data. Therefore to
determine whether the presence of these viral sequences
indeed represented previous human infection with
SV40, further characterization by amplifying different
regions of the SV40 genome, including the regulatory
region, and the carboxyl terminus of the Tag was per-
formed. This report summarizes the studies that used
the mesothelioma tissue bank generated at the National
Cancer Institute from a second series of 42 patients with
mesothelioma since the original report.4 The purpose of
such a study was to (1) verify the findings of SV40-like
DNA as previously reported, (2) attempt to characterize
other regions of the SV40 genome, and (3) determine
whether the amplified regions were consistent with
SV40 or another papovavirus.
Methods
Tissue samples and DNA preparation. From March 1993
to May 1995, portions of 42 consecutive cases of pleural and
peritoneal mesotheliomas were snap frozen in the operating
room. Patients gave informed consent for use of their tissue
in all cases. Genomic DNA was extracted with a commer-
cially available kit (Stratagene, La Jolla, Calif) with modifi-
cations to ensure for extraction of episomal DNA. These
modifications included spinning at 6000 rpm after addition of
phenol and no spooling of the DNA after precipitation with
ethanol. The DNA was centrifuged at 11,000 rpm in place of
spooling. Genomic DNA extracted from the SV40-induced
hamster mesothelioma, H9A, was used in all amplifications
as a positive control. 
Polymerase chain reaction analyses. The suitability of the
DNAs was tested with specific primers for the Alu
sequences and/or the b -globin gene (data not shown). The
polymerase chain reactions (PCRs) for SV40-sequence
amplifications were performed as previously described.4
Briefly, hot-start PCR was performed with Amplitaq DNA
polymerase (Perkin Elmer Cetus, Norwalk, Conn) according
to the vendor’s protocol. Thermocycling was performed by
denaturation at 94°C for 3 minutes, followed by cycling 45
times at 94°C for 1 minute, at 55° to 65oC for 1 minute, and
at 72°C for 1 minute. All amplifications were performed with
a positive control (H9A) and negative controls (water only)
to guard against possible misinterpretation because of cont-
aminating DNA. 
Specific amplification of the SV40 genome
TAG AMINO TERMINUS. PCR primers were used to amplify the
RB-pocket binding domain of Tag, which is the region that
binds and inactivates the retinoblastoma gene product.
Attempted amplification of this site was chosen because the
association of Tag with tumor suppressor genes is thought to
be important in SV40-mediated transformation. Therefore it
was unlikely that this region of Tag would be mutated or
deleted if Tag played any role in the development of mesothe-
lioma. Two sets of primer pairs were studied, including the
105 base pair (bp) specific for the RB-pocket binding
domain of Tag (Svfor3,Svrev; 5 ¢ -TGAGGCTACTGCT-
GACTCTCAACA-3¢ , 5¢ -GCATGACTCAAAAAACTTAG-
CAATTCTG-3¢ ) and another set of primers (SVfor2,Svrev;
5 ¢ -CTTTGGAGGCTTCTGGGATGCAACT-3 ¢ , 5 ¢ -GCAT-
GACTCAAAAAACTTAGCAATTCTG-3 ¢ ), which ampli-
fied the RB-pocket binding domain and the intron region of
SV40 large Tag (total size, 574 bp).5
SOUTHERN BLOT. PCR products were separated by elec-
trophoresis in 3% Nusieve/1% Seakem agarose gels and
transferred to a nylon membrane (Hybond N+; Amersham
Pharmacia Biotech, Piscataway, NJ). Filters were exposed to
Fig 1. Ethidium bromide gel of PCR products from amplifi-
cation for Tag amino terminus. Each lane represents a differ-
ent human mesothelioma, with molecular weight markers on
the edges. H9A: amplification product from SV40-induced
hamster mesothelioma, positive control.
Fig 2. Southern blot hybridization with a specific probe for
the RB-binding region of Tag after transfer of the gel seen in
Fig. 1. H2O: Lane containing only water, negative control.
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1200 mJ/cm2 of UV light, baked at 80°C under vacuum for 2
hours, and hybridized with 3 · 106 cpm/mL of a probe repre-
senting an internal region of the PCR products. SV-A Probe
(5¢ -GGAAAGTCCTTGGGGTCTTCTACC-3¢ ) was used for
the amino terminus of Tag amplified using the Svfor3
primers, and SV Probe (5 ¢ -ATGTTGAGAGTCAGCAB-
TAGCC-3¢ ) was used for the amino terminus of Tag ampli-
fied using the SVfor2 primers. Filters were then washed to a
final stringency of 0.5 · SSC/0.1% SDS at 52°C for 30 min-
utes and exposed 1 hour at room temperature.
TAG CARBOXYL TERMINUS. The carboxyl terminus of Tag is
highly variable in an evolutionary sense, because this region
shows considerable differences among different types of
polyomaviruses. This variability could be useful to identify
specific viruses and potentially to explain differences in site
specific replication. The primer sets for the Tag carboxyl
terminus (7,8;5 ¢ -GATGCTATTGCTTTATTT-3 ¢ , 5 ¢ -
GCCAGGAAAATGCTGATA-3¢ ) were used to amplify a
281-bp region which contained a unique BsaB1 restriction
site.6
SV40 REGULATORY REGION. Promoter regions are DNA
sequences that form a complex with RNA polymerase and
transcription factors to start the process of transcribing DNA
to RNA (transcription). Enhancer regions, when present, will
subsequently increase the level of transcription of the DNA
from a given promoter. It is known that the promoter/
enhancer (ie, regulatory) regions of polyomavirus such as
SV40 will influence what site or tissue the virus will repli-
cate. Moreover, the sequence and number of base pairs in the
regulatory region could be different among polyomaviruses
and could, if detected and sequenced, give insight as to which
specific virus was associated with mesothelioma. The primer
pairs R1 and R2 (5¢ -AATGTGTGTCAGTTAGGGTGTG,
TCCAAAAAAGCCTCCTCACTACTT-3 ¢ ) were used to
amplify a 315-bp region of the regulatory region for SV40.
The region amplified contained a unique Fok1 restriction
site.7
DNA cloning, isolation, and sequencing analysis. PCR
products amplified from 4 patients with the R1 and R2
primers were cloned into TA Cloning vector pCRII or PCR2.1
according to the protocol supplied with the original TA
Cloning kit (Invitrogen Corporation, Carlsbad, Calif). Re-
combinant DNA was prepared from ampicillin-resistant trans-
formants (E coli, INVaF ¢ One Shot; Invitrogen) with the
Wizard Plus Minipreps kit (Promega, Madison, Wis). Each
DNA was digested with BstXI, electrophoresed on a 7% poly-
acrylamide gel, and stained with ethidium bromide to identify
those clones containing an SV40 DNA insert. Clones contain-
ing SV40 DNA fragments of expected size were sequenced
manually by the method of Sanger and coworkers.8
Results
Tag amino terminus. SV40-like DNA was detected in
the mesothelioma specimens, confirming our findings
in our original report. There was an increased amplifi-
cation of the 105-bp segment of the amino terminus not
only on the ethidium bromide gels (30 of 42, 71%) but
also after hybridizing with a specific probe (31 of 33,
92%). The number of bands originally detected by
ethidium bromide with the primers that amplified a
larger segment of Tag was much lower. However,
Southern blot demonstrated a 25% amplification rate
for the larger region of amino terminus Tag with the
SVfor2 primers. Two species were identified in some
of the specimens representing amplification of the
intact segment (no intron deletion, 574 bp) or with an
intron deletion (324 bp).
Fig 3. Southern blot hybridization of the PCR products
obtained using the primers SVfor2 and SVrev for the amino
terminus region of Tag in human mesotheliomas. In addition
to the expected 574-bp product, some mesotheliomas contain
shorter sequences that are amplified with these SV40-specif-
ic primers and that hybridize with an SV40 probe. Sequence
analyses indicate that these sequences correspond to Tags
with deletions within the intron region.
Fig 4. Representative ethidium bromide gel of PCR product
of amplification for Tag carboxyl terminus region. Both
human mesothelioma specimens 2 and 10 amplify the same
product as the control hamster mesothelioma H9A, and after
digestion with the restriction endonuclease BsaB1, identical
products are formed (2c,10c, and H9Ac).
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Tag carboxyl terminus. Sixteen of the 42 specimens
(38%) contained sequences for the carboxyl terminus
of Tag. The digestion patterns after BsaB1 were identi-
cal to that seen with BsaB1 digestion of the product
obtained after carboxyl terminus amplification of the
H9A hamster mesothelioma. 
Regulatory sequences. Fifty-two percent (22 of 42
specimens) had amplification of the regulatory region
seen on ethidium bromide gels. The digestion patterns
after Fok1 were identical to that seen with Fok1 diges-
tion of the hamster mesothelioma control. 
Sequencing of the amplification product of the regu-
latory region in 4 patients revealed an identical
sequence to that seen with the hamster mesothelioma,
which, in fact, was derived from wild type strain SV40
776. 
Overall, 24% of the mesothelioma studies had ampli-
fication of all 3 regions (ie, amino and carboxyl termi-
nus for Tag as well as the regulatory region for SV40).
Discussion
This is the second report from our laboratory that
details the presence of viral DNA in human mesothe-
lioma. When we began this second set of investiga-
tions, there were no other reports in the literature that
verified these data, and because SV40 was not believed
to be a human pathogen, skepticism for a viral connec-
tion to this tumor was significant. The findings were
thought to be the result of “PCR contamination”
despite the fact that great efforts to avoid contamina-
tion by extracting the DNA from 1 SV40 free lab and
by running the PCR reactions and Southern blot exper-
iments in another building.
We felt that repeating the amplifications reported in
the first series in a second set of patients could not only
further convince us and others of the authenticity of
these findings but also would allow us to further iden-
tify other regions of the supposed viral genome if they
were present. Such an approach would narrow the field
of possible mesothelioma-associated viral candidates.
Since the publication of our original report, the
National Institutes of Health have sponsored a work-
shop specifically devoted to the issue of whether SV40
is a human pathogen and there have been confirmatory
data, specifically in patients with mesothelioma, that
sequences for the amino terminus of Tag are present.9
Unfortunately, however, there have been no data that
shed light on the origins of the mesothelioma-associat-
ed virus or the strain of the associated virus. The theo-
ries with regard to the origins of the virus, however,
have been the subject of a new series of controversial
epidemiologic and genetic studies caused by the known
Fig 5. Representative ethidium bromide gel of PCR product of amplification for SV40 regulatory
region. Each lane represents a different human mesothelioma, with molecular weight markers on the
edges. A 310-bp product of the regulatory region is amplified by the human mesotheliomas and is
cut identically as the control hamster mesothelioma H9A, with the restriction endonuclease Fok 1.
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contamination of the original poliovaccines and adeno-
vaccines with SV40.10-12
From the data in this report, it appears as if the finger-
print of SV40 itself is becoming more prominent as the
polyomavirus associated with mesothelioma. Not only
have we confirmed that the RB-pocket binding region of
the amino terminus of Tag is present in our specimens,
but we have also reported that the incidence is even
higher if one carefully extracts the DNA to make sure
one is not only harvesting DNA potentially integrated in
the genome but also existing episomally. The RB-pock-
et binding region is a highly conserved area because it
plays a critical role in the process of SV40 Tag-mediat-
ed transformation. Therefore mutations should not be
expected in this region if a Tag-like protein contributes
to tumor development. On the other hand, the intron
region could likely contain deletions and/or mutations,
which has been confirmed in osteosarcomas that express
Tag. This could, among other reasons, explain why the
percentage of positive amplification results were differ-
ent in this study between the primers that both amplify
the RB-binding region. 
The carboxyl end of Tag is highly variable in an evo-
lutionary sense, because this region shows consider-
able divergence in different papovaviruses. The
primers used in this study to amplify the carboxyl ter-
minus were specific for SV40 strain 776, further
strengthening the suggestion that the associated virus is
SV40. There are sequences at the carboxy terminus of
Tag that will determine the host range in cultured cells;
these sequences are different among different histolog-
ic organ types infected with SV40 (ie, kidney versus
brain). These data suggest that sequence differences at
the carboxy end of Tag may contribute to tissue-specif-
ic SV40 replication. How this occurs is unknown,
specifically as to why mesothelium would be targeted,
but Tag likely needs to interact with host cell transcrip-
tion factors in the process of switching from early to
late transcription, and transcription factors vary in a
cell type and tissue-specific fashion.
Further identification of the strain of virus could
come from characterization of the regulatory region. It
is significant in itself that regulatory regions compati-
ble with SV40 are present in 52% of the specimens,
and sequencing from 4 patients reveals that they have
base pair homology with wild type 776 SV40. 
This study does not give insight into the origin of the
sequences, nor does it implicate SV40 as a complete
carcinogen in mesothelioma. Morever, as described in
our previous study, most of these patients have asbestos
fibers in their lungs. These data do substantiate that
SV40 sequences are consistently present in mesothe-
lioma. Recent data, however, suggesting that natural
isolates of SV40 that originate in rhesus monkeys can
exist in multiple forms and that maternal-infant trans-
mission of the virus may occur heightens awareness for
this polyomavirus as a potential human pathogen.13,14
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Discussion
Dr Larry R. Kaiser (Philadelphia, Pa). Can you give us
some speculation as to whether you think that SV40 might be
involved in the pathogenesis of the disease? And we certain-
ly know that there is a percentage of patients who have no
asbestos exposure and yet mesotheliomas develop. We know,
for instance, that there is the occasional patient who has been
cured of Wilms tumor in whom mesothelioma has developed.
We know that WT1 is expressed in mesotheliomas. How
would you fit SV40 into the picture? How could there possi-
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bly be a link with asbestos? Maybe you could just postulate
on that for us.
Dr Pass. This is very controversial, both economically and
public healthwise. T antigen will combine with retinoblas-
toma gene product, as well as with the p53 protein product;
with these unactivated, you can potentially have transforma-
tion. 
Asbestos is a known fiber that causes not only chromoso-
mal problems within the human genome but also causes
immunosuppressive phenomena. In a situation where you
could have chromosomal breaks with oncogene amplification
or tumor suppressor gene loss, combined with a virus that
would work in an immunosuppressed setting and combined
with other tumor suppressor genes, the field may be possibly
set for mesothelial carcinogenesis. 
There are no data, however, that have demonstrated that
giving SV40 virus to human mesothelial cells, either with or
without asbestos, can transform cells into mesothelioma.
Dr Kaiser. Where are you heading with this now? I think
that it is intriguing both from a diagnostic and a therapeutic
possibility. I know in our work we have looked at basically
trying to say that T antigen of SV40 may be specific for
mesothelioma and perhaps if we are generating an immune
response against mesothelioma with some of the adenoviral
work, that we should see a response against SV40 T antigen.
So that is 1 potential strategy, and interestingly we have seen
that. Where are you going with this now?
Dr Pass. Our goal is the usual adoptive immunotherapy
approach: to identify specific epitopes for T cells that may be
expressed by T antigen, so that we can then take advantage
and use it with peptides to either amplify a patient’s own
immune system or amplify ex vivo lymphocytes that can be
supercharged to hone in on areas specifically that have T
antigen.
Dr David J. Sugarbaker (Boston, Mass). There is a study
that is going forward (from the NIH by Howard Strickler and
a group in the viral division) that is based on the concept that
SV40 is associated with a variety of different tumors (ie, head
and neck tumors and other tumors) and that this association
with mesothelioma may be more or less a background pick-
up, a contaminant. So the idea is to move forward with a care-
fully constructed set of what they call clean laboratories to be
sure there is not this background contaminant. 
Could you comment on that concept, particularly in light of
your hamster work, and give us an idea as to what you think
about it. 
Dr Pass. I am aware of that PCR working group because
essentially we were part of it in the beginning. The purpose
of the group is essentially not only to reconfirm our data but
also to set the PCR conditions, because there were questions
raised about how many amplifications you have to do. 
With regard to other tumors, it should not be propagated
that this is a common phenomenon. Our group has published
whether SV40 is present in other tumors; the other tumors it
is present in include childhood osteosarcomas, of which 40%
of them are present, and ependymomas and choroid plexus
tumors. This is not a phenomenon of other tumors. 
Dr Adelheid End (Vienna, Austria). Maybe I missed that
point in your lecture. Was there a difference between the
asbestos and the nonasbestos group concerning the incidence
of SV40? 
Dr Pass. Essentially if you look at these patients, and we
have done this in the first series, 95% of these patients will
have asbestos. We have a cohort of patients within this study
in whom indeed we have done fiber analysis who are low
asbestos and SV40 positive. We have not analyzed that
specifically. But at this point we cannot say that SV40 inde-
pendently, without a background of asbestos, does anything.
Dr Peter Goldstraw (London, England). Could you spec-
ulate as to why different fragments of the virus are persisting
in different tumors?
Dr Pass. I think that there is a possibility that there may be
a hybrid virus that is actually going on here that we do not
know truly. We may have a regulatory region that is com-
pletely the same as wild type SV40, but the amino terminus
and the carboxy terminus may be different because of muta-
tions; therefore you do not amplify it all the time. This may
also explain why you get certain tissue-specific characters.
Why do ependymomas or osteosarcomas develop in children,
while older individuals seem to have a propensity for having
this in mesotheliomas? These mutations may actually dictate
where the tumor may have its relevance.
